Exelixis Inc (EXEL)
36.70
-0.14
(-0.38%)
USD |
NASDAQ |
Mar 28, 16:00
36.68
-0.02
(-0.05%)
After-Hours: 20:00
Exelixis Enterprise Value: 9.160B for March 28, 2025
View 4,000+ Financial Data Types:
Add
Browse
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Halozyme Therapeutics Inc | 8.772B |
| Biomarin Pharmaceutical Inc | 13.09B |
| Catalyst Pharmaceuticals Inc | 2.481B |
| Incyte Corp | 9.569B |
| Blueprint Medicines Corp | 5.441B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 139.86M |
| Revenue (Quarterly) | 566.76M |
| Total Expenses (Quarterly) | 403.30M |
| EPS Diluted (Quarterly) | 0.48 |
| Gross Profit Margin (Quarterly) | 96.48% |
| Profit Margin (Quarterly) | 24.68% |
| Earnings Yield | 4.82% |
| Operating Earnings Yield | 6.35% |
| Normalized Earnings Yield | 5.418 |